{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:21:28Z","timestamp":1790112088234,"version":"4.0.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"DOI":"10.1007\/s00592-025-02635-8","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:26:08Z","timestamp":1767788768000},"page":"711-725","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens"],"prefix":"10.1007","volume":"63","author":[{"given":"Asad","family":"Jamal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6486-3093","authenticated-orcid":false,"given":"Suleman","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hammad","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munazza","family":"Sikandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inshal","family":"Jawed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Muneeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneeb Shad","family":"Mohmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaryab","family":"Bacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal Wazir","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aizaz Anwar","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Imad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Zulkaif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"2635_CR1","unstructured":"Facts & figures [Internet] International Diabetes Federation. [cited 2025 Oct 17]. Available from: https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/"},{"key":"2635_CR2","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB et al (2022) IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 183:109119","journal-title":"Diabetes Res Clin Pract"},{"issue":"Suppl 1","key":"2635_CR3","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2337\/dc23-S002","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D et al (2023) Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care 46(Suppl 1):S19\u201340","journal-title":"Diabetes Care"},{"issue":"11","key":"2635_CR4","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM et al (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 45(11):2753\u20132786","journal-title":"Diabetes Care"},{"issue":"7","key":"2635_CR5","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/dom.14008","volume":"22","author":"H Hussein","year":"2020","unstructured":"Hussein H, Zaccardi F, Khunti K, Davies MJ, Patsko E, Dhalwani NN et al (2020) Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis. Diabetes Obes Metab 22(7):1035\u20131046","journal-title":"Diabetes Obes Metab"},{"key":"2635_CR6","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/DMSO.S141235","volume":"10","author":"MV Sikirica","year":"2017","unstructured":"Sikirica MV, Martin AA, Wood R, Leith A, Piercy J, Higgins V (2017) Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes Targets Ther 10:403\u2013412","journal-title":"Diabetes Metab Syndr Obes Targets Ther"},{"issue":"1","key":"2635_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1185\/03007990903421994","volume":"26","author":"CE Cooke","year":"2010","unstructured":"Cooke CE, Lee HY, Tong YP, Haines ST (2010) Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin 26(1):231\u2013238","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"2635_CR8","first-page":"1915","volume":"12","author":"TA B\u00e6kdal","year":"2021","unstructured":"B\u00e6kdal TA, Breitschaft A, Donsmark M, Maarbjerg SJ, S\u00f8ndergaard FL, Borregaard J (2021) Effect of various dosing conditions on the pharmacokinetics of oral semaglutide, a human glucagon-like peptide-1 analogue in a tablet formulation. Diabetes Ther Res Treat Educ Diabetes Relat Disord 12(7):1915\u20131927","journal-title":"Diabetes Ther Res Treat Educ Diabetes Relat Disord"},{"issue":"47","key":"2635_CR9","doi-asserted-by":"publisher","first-page":"29959","DOI":"10.1073\/pnas.2014879117","volume":"117","author":"T Kawai","year":"2020","unstructured":"Kawai T, Sun B, Yoshino H, Feng D, Suzuki Y, Fukazawa M et al (2020) Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proc Natl Acad Sci U S A 117(47):29959\u201329967","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2635_CR10","doi-asserted-by":"publisher","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab 46:101102","journal-title":"Mol Metab"},{"key":"2635_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"2635_CR12","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"2635_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jclinepi.2015.12.006","volume":"74","author":"N Santesso","year":"2016","unstructured":"Santesso N, Carrasco-Labra A, Langendam M, Brignardello-Petersen R, Mustafa RA, Heus P et al (2016) Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments. J Clin Epidemiol 74:28\u201339","journal-title":"J Clin Epidemiol"},{"key":"2635_CR14","doi-asserted-by":"publisher","unstructured":"Shao, S., Kuo, L., Huang, Y., Lai, P., & Chi, C. (2023). Using Grading of Recommendations Assessment, Development, and Evaluation (GRADE) to rate the certainty of evidence of study outcomes from systematic reviews: A quick tutorial. Dermatologica Sinica, 41, 3\u20137. https:\/\/doi.org\/10.4103\/ds.ds-d-22-00154","DOI":"10.4103\/ds.ds-d-22-00154"},{"issue":"7414","key":"2635_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560","journal-title":"BMJ"},{"issue":"3","key":"2635_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177\u2013188","journal-title":"Control Clin Trials"},{"issue":"1","key":"2635_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12874-017-0315-7","volume":"17","author":"J Wetterslev","year":"2017","unstructured":"Wetterslev J, Jakobsen JC, Gluud C (2017) Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol 17(1):39","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"2635_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","volume":"61","author":"J Wetterslev","year":"2008","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C (2008) Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol 61(1):64\u201375","journal-title":"J Clin Epidemiol"},{"issue":"10400","key":"2635_CR19","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/S0140-6736(23)01302-8","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Hsia S, Eyde S, Liu R, Ma X, Konig M et al (2023) Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study. Lancet Lond Engl 402(10400):472\u2013483","journal-title":"Lancet Lond Engl"},{"issue":"10","key":"2635_CR20","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R et al (2023) Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med 389(10):877\u2013888","journal-title":"N Engl J Med"},{"issue":"11","key":"2635_CR21","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","volume":"393","author":"J Rosenstock","year":"2025","unstructured":"Rosenstock J, Hsia S, Nevarez Ruiz L, Eyde S, Cox D, Wu WS et al (2025) Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med 393(11):1065\u20131076","journal-title":"N Engl J Med"},{"issue":"2","key":"2635_CR22","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1002\/osp4.743","volume":"10","author":"D Dutta","year":"2024","unstructured":"Dutta D, Nagendra L, Anne B, Kumar M, Sharma M, Kamrul-Hasan ABM (2024) Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: a systematic review and meta-analysis. Obes Sci Pract 10(2):e743","journal-title":"Obes Sci Pract"},{"key":"2635_CR23","doi-asserted-by":"publisher","unstructured":"Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796\u20131806. https:\/\/doi.org\/10.1056\/NEJMoa2511774","DOI":"10.1056\/NEJMoa2511774"},{"issue":"1","key":"2635_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11883-025-01350-7","volume":"27","author":"H Abu-Nejim","year":"2025","unstructured":"Abu-Nejim H, Becker RC (2025) Current perspectives on GLP-1 agonists in contemporary clinical practice from science and mechanistic foundations to optimal translation. Curr Atheroscler Rep 27(1):99","journal-title":"Curr Atheroscler Rep"},{"key":"2635_CR25","first-page":"305","volume":"17","author":"TW Fredrick","year":"2025","unstructured":"Fredrick TW, Camilleri M, Acosta A (2025) Pharmacotherapy for obesity: recent updates. Clin Pharmacol Adv Appl 17:305\u2013327","journal-title":"Clin Pharmacol Adv Appl"},{"issue":"11","key":"2635_CR26","first-page":"1761","volume":"60","author":"I Pantea","year":"2024","unstructured":"Pantea I, Repanovici A, Andreescu O (2024) The influence of GLP1 on body weight and glycemic management in patients with diabetes-A scientometric investigation and visualization study. Med Kaunas Lith 60(11):1761","journal-title":"Med Kaunas Lith"},{"issue":"6","key":"2635_CR27","first-page":"e659","volume":"31","author":"A Repanovici","year":"2024","unstructured":"Repanovici A, Rogozea LM, Pantea I (2024) GLP-1 and body weight: a scientometric analysis about how to select the best articles containing pharmacological treatment methods. Am J Ther 31(6):e659\u2013e668","journal-title":"Am J Ther"},{"issue":"9","key":"2635_CR28","first-page":"1809","volume":"41","author":"P Sedrak","year":"2025","unstructured":"Sedrak P, Verma R, Verma M, Connelly KA (2025) Evolving role of double and triple therapy with GLP-1 receptor agonists in obesity and cardiovascular disease. Can J Cardiol 41(9):1809\u20131822","journal-title":"Can J Cardiol"},{"issue":"7","key":"2635_CR29","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/dom.14700","volume":"24","author":"S Verma","year":"2022","unstructured":"Verma S, Al-Omran M, Leiter LA, Mazer CD, Rasmussen S, Saevereid HA et al (2022) Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metab 24(7):1288\u20131299","journal-title":"Diabetes Obes Metab"},{"key":"2635_CR30","doi-asserted-by":"crossref","unstructured":"Sklepinski SM, Deng Y, Swarna KS, Herrin J, Polley EC, Neumiller JJ et al Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial. Diabetes Res Clin Pract [Internet]. 2025 Nov [cited 2025 Oct 17];229(112910). Available from: https:\/\/www.scopus.com\/pages\/publications\/105017713764","DOI":"10.1016\/j.diabres.2025.112910"},{"issue":"1","key":"2635_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12933-023-01800-z","volume":"22","author":"S Piccini","year":"2023","unstructured":"Piccini S, Favacchio G, Panico C, Morenghi E, Folli F, Mazziotti G et al (2023) Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study. Cardiovasc Diabetol 22(1):69","journal-title":"Cardiovasc Diabetol"},{"key":"2635_CR32","doi-asserted-by":"publisher","first-page":"1535134","DOI":"10.3389\/fcvm.2025.1535134","volume":"12","author":"Y Turkistani","year":"2025","unstructured":"Turkistani Y (2025) Glucagon-like peptide-1 receptor agonists: a review from a cardiovascular perspective. Front Cardiovasc Med 12:1535134","journal-title":"Front Cardiovasc Med"},{"issue":"9","key":"2635_CR33","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1111\/dom.15150","volume":"25","author":"E Pratt","year":"2023","unstructured":"Pratt E, Ma X, Liu R, Robins D, Coskun T, Sloop KW et al (2023) Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes Obes Metab 25(9):2642\u20132649","journal-title":"Diabetes Obes Metab"},{"key":"2635_CR34","doi-asserted-by":"publisher","first-page":"155710","DOI":"10.1016\/j.metabol.2023.155710","volume":"149","author":"P Karakasis","year":"2023","unstructured":"Karakasis P, Patoulias D, Pamporis K, Stachteas P, Bougioukas KI, Klisic A et al (2023) Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism 149:155710","journal-title":"Metabolism"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02635-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00592-025-02635-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-025-02635-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T01:40:04Z","timestamp":1776649204000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00592-025-02635-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["2635"],"URL":"https:\/\/doi.org\/10.1007\/s00592-025-02635-8","relation":{},"ISSN":["1432-5233"],"issn-type":[{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not required for this systematic review and meta-analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent for publication"}}]}}